While some randomized controlled trials (RCTs) have verified the safety and efficacy of targeted therapies or combined targeted endocrine therapy for patients with HR + /HER2 − advanced breast cancer, the absence of head-to-head comparisons prevents us from determining which treatment offers the greatest survival advantage. This evidence concerns the gene HR and breast cancer.